double blind
[대역어] 이중 블라인드
[용어속성] Term
[용어속성] Term
Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial
Randomized Controlled Trial
[키워드] acute respiratory syndrome
administration
Analysis
antiparasitic drug
Arm
assigned
Coronavirus-2
COVID-19
dose
double blind
Efficacy
enrolment
hospitalized patient
in viral
In-vitro
intention-to-treat population
Intervention
Ivermectin
Mild
Mild-to-moderate
Moderate COVID-19
modified intention-to-treat
negativity
occurred
outcome
Patient
patients randomized
Placebo
placebo-controlled trial
positive RT-PCR
Primary outcome
Randomized
Randomized controlled trial
reducing
RT-PCR
Safety
SARS-CoV-2
Serious Adverse Event
Serious Adverse Events
significantly
Single-dose
statistical significance
treating COVID-19
Viral load
Viral load.
were assessed
[DOI] 10.1016/j.jiac.2021.08.021 PMC 바로가기 [Article Type] Randomized Controlled Trial
[DOI] 10.1016/j.jiac.2021.08.021 PMC 바로가기 [Article Type] Randomized Controlled Trial
Acute estradiol and progesterone therapy in hospitalised adults to reduce COVID-19 severity: a randomised control trial
Randomized Controlled Trial
[키워드] addition
Admission
adverse events
Anti-inflammatory
antibody production
approved drug
Biology
center
clinically
Corticosteroids
COVID-19
death
determine
disease severity
double blind
drug
Efficacy
Ethical approval
Ethics
evaluate
food
general endocrinology
Hospital stay
hospitalised
Hospitalised patients
HRT
HRT.
immune response
immune tolerance
include
Infectious diseases
Inflammatory biomarker
intramuscular
mechanical ventilation
Medicine
mitigate
New
New Orleans
Occurrence
Oestradiol
outcome
Participants
Patient
peer-reviewed
Phase 2
Placebo
placebo-controlled
primary endpoint
Primary outcome
progesterone
proportion
randomised
readmission
reduce
reducing
Result
Sample size
secondary
Sex
sex steroids &
Sponsor
Standard of care
steroid
subjects
submitted
the WHO
therapeutic option
therapy
Trial
university
USA
was obtained
WHO ordinal scale
[DOI] 10.1136/bmjopen-2021-053684 PMC 바로가기 [Article Type] Randomized Controlled Trial
[DOI] 10.1136/bmjopen-2021-053684 PMC 바로가기 [Article Type] Randomized Controlled Trial
Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial
성인 외래 환자의 covid-19 치료를 위한 흡입 및 비강 ciclesonide: CONTAIN 2상 무작위 대조 시험
Clinical Trial
[키워드] 95% confidence interval
adjusted
adult outpatient
adult outpatients
assigned
benefit
Chain Reaction
Ciclesonide
Combination
Comorbidities
conducted
control group
Corticosteroid
Corticosteroids
cough
determine
dose
double blind
Dyspnoea
Evidence
Fever
Follow-up
increase in
Inhaled
interquartile range
intervention group
intranasal
median age
modified intention-to-treat
nasal
not differ
Older
outcome
participant
Placebo
placebo controlled trial
polymerase chain
polymerase chain reaction
presenting
Primary outcome
proportion
randomisation
randomised
randomised controlled trial
Randomly
receive
Research
resolution of symptom
respiratory symptom
respiratory symptoms
Result
risk
risk difference
saline placebo
Sex
significantly
statistically significant
stratified
study drug
symptom resolution
treat
treatment of COVID-19
Trial
women
[DOI] 10.1136/bmj-2021-068060 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1136/bmj-2021-068060 PMC 바로가기 [Article Type] Clinical Trial
Epidural morphine in COVID ARDS patients with high respiratory drive: a structured summary of a study protocol for a randomised controlled trial
높은 호흡 드라이브가 있는 COVID ARDS 환자의 경막외 모르핀: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] 1:1
28-day mortality
Abnormalities
acceptance
administer
Administered
Admission
Adult patient
Adult patients
allocation
ARDS patient
aseptic technique
assistant
average
blind
Blinding
both group
both groups
catheterization
Coagulation
comparator Patients
control group
COVID
COVID 19 patient
COVID 19 patients
COVID-19
criteria
CTRI
death
discharge
dissemination
dose
doses
double blind
Dyspnoea
element
Endotracheal intubation
Epidural
epidural catheter
Epidural morphine
epidural space
Escalation
exclusion criteria
fixed
fraction
greater
Group allocation
HCO
hypoventilation
Hypoxemia
ICU
ICU patient
inclusion criteria
India
injection
Intervention
intervention group
intubation
involved
list
Local
maximum
mechanical ventilation
Medical Science
Medical Sciences
Metabolic acidosis
minimum
morphine
morphine sulphate
Mortality
NIV
non-invasive ventilation
number
Nurse
objective
outcome
Pain
parameters
participant
Patient
Patient self-induced lung injury
patients with COVID19
physician
Placebo
protocol
random
randomisation
randomised
randomised controlled trial
recruited
reduce
Registered
registry
Research
respiratory
respiratory acidosis
Respiratory drive
respiratory parameters
resulting
Sample size
sealed
second dose
secondary
Secondary outcomes
Sedation
Sepsis
severe hypoxemia
sitting position
skin
Source
Study protocol
sulphate
supplementary material
team
the patient
Trial
ventilator parameters
website
with COVID-19
[DOI] 10.1186/s13063-021-05570-5 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-021-05570-5 PMC 바로가기 [Article Type] Letter
Mometasone furoate nasal spray in the treatment of patients with COVID-19 olfactory dysfunction: A randomized, double blind clinical trial
Randomized Controlled Trial
[키워드] analysis
analyzed
Anosmia
assigned
baseline
both group
change
Clinical characteristics
clinical trial
Combination
Corticosteroids
COVID-19
demographics
double blind
dysfunction
evaluate
identification
interval
Loss of Smell
Mometasone furoate
nasal
no significant difference
not significant
olfactory
olfactory dysfunction
olfactory dysfunction.
Patient
patients with COVID-19
Primary outcome
Prospective clinical trial
Randomized
Randomly
recruited
severity
significant difference
Smell
Sodium chloride
statistically significant difference
subject
Test
Treatment
two group
University of Pennsylvania
Visual
were used
[DOI] 10.1016/j.intimp.2021.107871 PMC 바로가기 [Article Type] Randomized Controlled Trial
[DOI] 10.1016/j.intimp.2021.107871 PMC 바로가기 [Article Type] Randomized Controlled Trial
Optimization and validation of RT-LAMP assay for diagnosis of SARS-CoV2 including the globally dominant Delta variant
전 세계적으로 지배적 인 델타 변이체를 포함하여 SARS-COV2의 진단을위한 RT-LAMP 분석의 최적화 및 검증
Research
[키워드] acute respiratory syndrome coronavirus
amplification
Analysis
B.1.1.7
B.1.1.7 (Alpha)
B.1.351
B.1.351 (Beta)
B.1.427
B.1.429 (Epsilon)
B.1.525
B.1.525 (Eta)
B.1.526
B.1.526 (Iota)
B.1.617.1
B.1.617.1 (Kappa)
B.1.617.2
B.1.617.2 (Delta)
causative agent
condition
conserved
conserved regions
coronavirus
coronavirus 2
COVID-19
COVID-19 pandemic
delta variant
development
Diagnosis
diagnosis of COVID-19
discrimination
DNA polymerase
dominant
double blind
double blind study
evaluated
gold
gold standard
Health Organization
include
infected individual
infected individuals
Isolation
isothermal
LAMP
Lineage
Loop-mediated isothermal amplification
molecular
Molecular diagnosis
objective
optimization
P.1
P.1 (Gamma)
P.2
P.2 (Zeta)
P.3 (Theta)
pathogenic coronaviruses
Patient
PCR
primer binding site
primer binding sites
primer set
Primers
real time PCR
Region
respiratory
Result
RT-LAMP
SARS-CoV-2
SARS-CoV2
severe acute respiratory syndrome coronavirus 2
Spread
supplementary material
Testing
the disease
time
variants
variants of concern
variants of interest
Visualization
VoC
WHO
World Health Organization
[DOI] 10.1186/s12985-021-01642-9 PMC 바로가기 [Article Type] Research
[DOI] 10.1186/s12985-021-01642-9 PMC 바로가기 [Article Type] Research
COVID-19 Vaccine Passport and International Traveling: The Combined Effect of Two Nudges on Americans’ Support for the Pass
Randomized Controlled Trial
[키워드] Affect
American
Combined
COVID
COVID-19
COVID-19 vaccine
double blind
Effect
effective
experiment
implication
Intention
Interaction
interaction between nudges
International
nudges
Pass
Passport
peer effect
Randomized
status quo bias
Support
supported
vaccine passport
[DOI] 10.3390/ijerph18168800 PMC 바로가기 [Article Type] Randomized Controlled Trial
[DOI] 10.3390/ijerph18168800 PMC 바로가기 [Article Type] Randomized Controlled Trial
Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial
Randomized Controlled Trial
[키워드] 1:1
95% CI
acute respiratory syndrome
adverse outcome
age
clinical evolution
co-morbidity
conducted
coronavirus
coronavirus disease
Coronavirus disease 2019
COVID-19
COVID-19 patient
death
decrease
determine
disease
double blind
double-blind placebo-controlled trial
end point
End points
France
groups
high risk
Hydroxychloroquine
hydroxychloroquine group
ill patient
intensive care
intention-to-treat population
interquartile range
Invasive mechanical ventilation
median age
Mild
Mild-to-moderate
moderate
Moderate COVID-19
Mortality
multicentre
occurred
older patient
Oxygen therapy
pandemic
Patient
patients treated
per day
Placebo
placebo-controlled
positive
primary end point
randomization
Randomized
Randomized controlled trial
receive
receiving
required
risk
risk factor
SARS-CoV-2 RT-PCR test
secondary
Severe acute respiratory syndrome coronavirus 2.
supplemental oxygen
the placebo group
Trial
two group
viral shedding
virological outcome
were excluded
worsening
[DOI] 10.1016/j.cmi.2021.03.005 PMC 바로가기 [Article Type] Randomized Controlled Trial
[DOI] 10.1016/j.cmi.2021.03.005 PMC 바로가기 [Article Type] Randomized Controlled Trial
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial
SARS-CoV-2 백신(비활성화, Vero 세포)의 효능과 안전성을 평가하기 위한 무작위 이중 맹검 위약 대조 임상 3상 시험: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] 1:1
24 hour
24 hours
95% confidence interval
Activation
Active surveillance
administration
Administrative Personnel
Adverse
adverse event
adverse events
Adverse reaction
Adverse reactions
African green monkey
age
Algorithm
Aluminium
aluminium hydroxide
anaphylaxis
Antibody test
Antibody titer
Antigen
Arm
asplenia
assigned
assumed
assumption
Autoimmune
baseline
bleeding disorders
Blinding
blood product
blood products
blood sample
Blood samples
breastfeeding women
breath
carried
Cell culture
China
chloride
Clinical efficacy
clinical trial
code
Cohort
cohorts
comparator
consent form
cooperation
Corticosteroid
Corticosteroids
COVID-19
COVID-19 cases
COVID-19 disease
COVID-19 symptoms
COVID-19 test
criteria
Critical
CRO
Data and Safety Monitoring Board
Day
development
diary
dihydrogen
DIHYDROGEN PHOSPHATE
disease
disodium
disodium hydrogen phosphate
dissemination
dose
dose of vaccination
double blind
double-blind
double-blind study
Efficacy
Efficacy and safety
element
eligible
Endpoint
enrolled
enrolment
ethics committee
evaluate
event
excluded
exclusion criteria
expected
Follow-up
follow-up period
Frequency
Gender
genders
green monkey
group
groups
healthcare
Healthcare professional
healthcare professionals
higher risk
HIV infection
hospital
Hospitalization
hydrogen
Hydrogen phosphate
hydroxide
hypersensitivity
identity
IgG level
IgG levels
IgG test
immunogenicity
Immunoglobulin
immunoglobulins
immunosuppressive
immunosuppressive therapy
inactivated
Inactivated Vaccines
incidence
incidence rate
include
Inclusion
individual
information
informed consent form
initiated
Interactive Web Response System
intramuscular dose
investigator
IWRS
IWRS system
kidney
knowledge
Local
local reactions
management
medical doctors
medical emergency
Ministry of Health
mortality rates
neutralizing antibody
Neutralizing antibody titer
Novel coronavirus
number
Nurses
objective
Omega
Other
participant
PCR
PCR positivity
performed
Phase III Clinical Trial
phosphate
Placebo
placebo group
placebo-controlled
positive
pregnancy test
pregnant
preparation
primary efficacy endpoint
professional
proportion
protocol
randomised
randomised controlled trial
randomised placebo controlled trial
randomization
Randomized
Randomly
Reactions
receive
recorded
regimens
Registration
reported
response
risk
risk of infection
RT-PCR
RT-PCR test
RT-PCR tests
Safety Monitoring Board
Sample size
SARS-CoV-2 vaccine
SARS-CoV-2 virus
screened
second dose
secondary
Secondary objectives
Serious Adverse Event
Serious Adverse Events
seroconversion rate
Seropositivity
severity
severity of COVID-19
shown
Sinovac
sodium
Sodium chloride
sodium dihydrogen phosphate
Sponsor
status
study group
Study protocol
subject
subject’
supplementary material
Symptom
symptomatic
symptomatic case
symptomatic cases
System
systemic adverse reaction
the ethics committee
the timing
the vaccine
therapy
Treatment
treatment arm
Trial
Turkey
two-sided
vaccinated groups
vaccination
Vaccine
Vero
Vero Cell
Web
website
width
with COVID-19
within 6 months
[DOI] 10.1186/s13063-021-05180-1 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-021-05180-1 PMC 바로가기 [Article Type] Letter